tiprankstipranks
Advertisement
Advertisement

CTOR Stock Latest News

Citius Oncology provides update on commercial launch of Lymphir
The FlyCitius Oncology provides update on commercial launch of Lymphir
1d ago
CTOR
CTXR
Citius Oncology Highlights Promising LYMPHIR Combo Phase 1 Data
PremiumCompany Announcements
Citius Oncology Highlights Promising LYMPHIR Combo Phase 1 Data
2M ago
8K
CTOR
Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO
PremiumThe Fly
Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO
2M ago
CTOR
CTXR
Citius Oncology registers to sell 32.93M shares of common stock for holders
PremiumThe Fly
Citius Oncology registers to sell 32.93M shares of common stock for holders
2M ago
CTOR
Buy Rating Reaffirmed on Lymphir’s Promising Early Data; $4 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Lymphir’s Promising Early Data; $4 Price Target Maintained
2M ago
CTOR
Citius Oncology Secures New Financing to Support LYMPHIR
PremiumCompany AnnouncementsCitius Oncology Secures New Financing to Support LYMPHIR
3M ago
8K
CTOR
Citius Oncology Begins First European Expansion of LYMPHIR
Premium
Company Announcements
Citius Oncology Begins First European Expansion of LYMPHIR
3M ago
8K
CTOR
Citius Oncology announces initial shipment of LYMPHIR to Europe
Premium
The Fly
Citius Oncology announces initial shipment of LYMPHIR to Europe
3M ago
CTOR
CTXR
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms
PremiumCompany Announcements
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms
3M ago
8K
CTOR
Citius Oncology highlights early LYMPHIR commercial traction, expansion
PremiumCompany Announcements
Citius Oncology highlights early LYMPHIR commercial traction, expansion
4M ago
8K
CTOR
Citius Oncology provides commercial update on lymphir launch
PremiumThe Fly
Citius Oncology provides commercial update on lymphir launch
4M ago
CTOR
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
PremiumCompany Announcements
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
4M ago
8K
CTOR
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
PremiumThe FlyCitius Oncology’s Lymphir shows positive results in gynecologic cancers
4M ago
CTOR
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
Premium
Company Announcements
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
5M ago
8K
CTOR
Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR
Premium
The Fly
Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR
5M ago
CTOR
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
PremiumThe Fly
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
5M ago
CTOR
CTXR
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
PremiumThe Fly
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
5M ago
CTOR
CTXR
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
PremiumThe Fly
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
5M ago
CTOR
CTXR
CTOR Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CTOR Earnings this Week: How Will it Perform?
5M ago
CTOR
Citius files to sell shares of common stock underlying warrants for holders
PremiumThe FlyCitius files to sell shares of common stock underlying warrants for holders
7M ago
CTOR
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption
Premium
Company Announcements
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption
7M ago
CTOR
Citius Oncology reports FY25 EPS (34c) vs. (31c) last year
Premium
The Fly
Citius Oncology reports FY25 EPS (34c) vs. (31c) last year
7M ago
CTOR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >